14
Oct
2015
Introducing Signal: The Stat Podcast I’m Co-Hosting With Meg Tirrell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
12
Oct
2015
Who Deserves To Be Called a Founder, and Who Doesn’t?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Oct
2015
Vertex Takes Heat, Valeant Takes Even More, and Express Scripts Cuts a Deal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Oct
2015
GlaxoSmithKline: A Bunch of Bozos, Or Crazy Like a Fox?
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
2
Oct
2015
Fallout from the Drug Pricing Fiasco, the New Thing in Genome Editing & More
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
1
Oct
2015
The Next Macro (Phage) Thing in Immuno-Oncology
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
28
Sep
2015
What Happens After The Gouging? Lock Pharma & The Payers in a Swiss Hotel
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
25
Sep
2015
The Mother of All Drug Pricing Controversies, Slingshots at FDA Nominee, and Nobel Handicapping
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
23
Sep
2015
A Timeline of the Turing Pharma Controversy
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
22
Sep
2015
Seattle Subscribers: Come Talk Biotech Today at the TR Meetup
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
21
Sep
2015
The McKinsey Alumni: Where Are They Wielding Influence?
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
18
Sep
2015
Just Snags $15M From Merck, Lilly, ARCH for Low-Cost Biotech Drugs
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
18
Sep
2015
New FDA Commish, Lilly’s Diabetes Stunner, and a Dust-Up Over Immortality
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
14
Sep
2015
Interlocking Relationships Make VC and Pharma Go Round, Not Just Science
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
11
Sep
2015
Post-Labor Day Hangovers, Ipi-Nivo Combo Data & the PCSK9 Pricing Debate
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
8
Sep
2015
Medical Device Innovation Is on Life Support. What Will Revive It?
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
4
Sep
2015
Insider Selling at Biotech’s Highflying IPOs From 2013-2014
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
1
Sep
2015
Join Me for the TR San Francisco Launch Party Oct. 20
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
31
Aug
2015
What Happens After the Hype? A Few Survive the ‘Trough of Disillusionment’
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
28
Aug
2015
Insider Stock Sales at Biotech’s Big Six: See Who’s Cashing Out the Most
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share: